Results 171 to 180 of about 49,593 (258)

Why are the police against drug policy liberalisation? [PDF]

Nordisk Alkohol Nark, 2023
Johnstad PG.
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Does solo publication still make sense? : Single-authored publications have been essential to scientific progress but are now facing extinction. [PDF]

EMBO Rep
Rull V.
europepmc   +1 more source

Shifting drug markets in North America - a global crisis in the making? [PDF]

Int J Ment Health Syst, 2023
Meyer M, Westenberg JN, Jang KL, Choi F, Schreiter S, Mathew N, King C, Lang UE, Vogel M, Krausz RM.   +9 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

The leading causes of death in the US and Mexico's pediatric population are related to violence: a note on secondary analyses of registered deaths from 2000 to 2022. [PDF]

Front Public Health
Castilla-Peon MF, Rendón PL, Gonzalez-Garcia N.   +2 more
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

2024 international trauma care forum guest nation symposium: gunshot injuries. [PDF]

OTA Int
Leal JA, Hayda R, Biliavskyi V, Klapchuk Y, Gomez A, Whiting P.   +5 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Yellow fever in children and adolescents amid the South American outbreak, 2024/2025. [PDF]

New Microbes New Infect
Rodriguez-Morales AJ, Torres-Hernández D, Guevara ME, Chang-Cojulun A, Brea-Del Castillo J, Rios-Blanco R, Mérida-Barrios MI, Palmieri M, Avila-Agüero ML.   +8 more
europepmc   +1 more source